2. Disease Areas
  3. Cancer Neurological, Eye or Ear Disease
  4. CNS Neoplasm
  5. Neuroblastoma

Neuroblastoma

Neuroblastoma is a type of cancer that develops from immature nerve cells (neuroblasts) found in several areas of the body. It most frequently arises from the adrenal medulla or along the paravertebral sympathetic chain. During embryogenesis, neural crest cells migrate from the dorsal neural tube, undergoing epithelial-to-mesenchymal transition before differentiating into components of the sympathetic nervous system and adrenal medulla. A subset of Schwann cell precursors—often referred to as “bridge cells”—can differentiate either into chromaffin cells or into sympathoadrenal neuroblasts, which continue their maturation postnatally.

Neuroblastoma (1):

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-15676
    Idasanutlin 1229705-06-9 99.93%
    Idasanutlin (RG7388) is an orally bioavailable MDM2 inhibitor with an IC50 of 6 nM. Idasanutlin disrupts MDM2-p53 binding, stabilizes and activates p53, triggering cell cycle arrest, apoptosis, and reduced cancer cell viability. Idasanutlin reduces EGFR protein expression and phosphorylation, suppresses downstream SHP2, MEK1/2, ERK1/2, AKT, mTOR, p70(S6K1), and S6 signaling. Idasanutlin induces mitochondrial ROS production, drives p38 MAPK phosphorylation, upregulates NOXA, and mediates caspase-3-dependent apoptosis and gasdermin E-mediated pyroptosis. Idasanutlin can be used for the research of TP53-mutant non-small cell lung cancer, T-cell acute lymphoblastic leukemia, colorectal carcinoma, melanoma, diffuse large B-cell lymphoma, mantle cell lymphoma, non-Hodgkin lymphoma, severe fever with thrombocytopenia syndrome, neuroblastoma, acute lymphoblastic leukemia, relapsed or refractory acute myeloid leukemia, osteosarcoma, solid tumors, and hematological tumors.
    Idasanutlin